These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19793692)

  • 1. [Antitumor activity of zoledronic acid].
    Tamási L
    Magy Onkol; 2009 Sep; 53(3):269-71. PubMed ID: 19793692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal management of metastatic bone disease.
    Major P
    Eur J Oncol Nurs; 2007; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates in lung cancer: can they provide benefits beyond prevention of skeletal morbidity?
    Hirsh V
    Anticancer Agents Med Chem; 2012 Feb; 12(2):137-43. PubMed ID: 21864233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid: past, present and future roles in cancer treatment.
    Saad F
    Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of a primary pulmonary adenocarcinoma after zoledronic acid monotherapy.
    Nagao S; Hattori N; Fujitaka K; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Haruta Y; Murai H; Kohno N
    Hiroshima J Med Sci; 2011 Mar; 60(1):7-9. PubMed ID: 21675041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Sakurai T
    Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid in lung cancer with bone metastases: a review.
    Isla D; Afonso R; Bosch-Barrera J; Martínez N
    Expert Rev Anticancer Ther; 2013 Apr; 13(4):421-6. PubMed ID: 23560837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid: a new parenteral bisphosphonate.
    Li EC; Davis LE
    Clin Ther; 2003 Nov; 25(11):2669-708. PubMed ID: 14693298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antitumor properties of the bisphosphonate zoledronate and potential therapeutic implications in the clinic].
    Clézardin P
    Bull Cancer; 2010 Aug; 97(8):937-49. PubMed ID: 20595092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapeutic agents for the treatment of bone diseases.
    Lipton A
    Expert Opin Biol Ther; 2005 Jun; 5(6):817-32. PubMed ID: 15952912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R; Gnant M; Morgan G; Clezardin P
    J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid in the management of metastatic bone disease.
    Santini D; Fratto ME; Vincenzi B; Galluzzo S; Tonini G
    Expert Opin Biol Ther; 2006 Dec; 6(12):1333-48. PubMed ID: 17223741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of bisphosphonates on pain and quality of life in patients with bone metastases.
    Costa L; Major PP
    Nat Clin Pract Oncol; 2009 Mar; 6(3):163-74. PubMed ID: 19190592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis.
    Daubiné F; Le Gall C; Gasser J; Green J; Clézardin P
    J Natl Cancer Inst; 2007 Feb; 99(4):322-30. PubMed ID: 17312309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
    Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
    Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
    Morgan C; Lewis PD; Jones RM; Bertelli G; Thomas GA; Leonard RC
    Acta Oncol; 2007; 46(5):669-77. PubMed ID: 17562444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.